Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, October 10, 2017
Pertinax Pharma announced the commercial launch of its proprietary Pertinax technology, which provides controlled and sustained delivery of CHX.
read more
Friday, November 09, 2018
Personalis announced the launch of its universal cancer immunogenomics platform, ImmunoID NeXT.
read more
Wednesday, November 20, 2019
Personalis has announced a collaboration with Merck KGaA, Darmstadt, Germany to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies.
read more
Friday, February 03, 2023
Personalis, Inc., a provider of advanced genomics for precision oncology, and Moderna, Inc. announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/...
read more
Wednesday, February 26, 2020
Perrigo and Catalent Pharma Solutions announced the FDA has approved Perrigo’s ANDA for generic albuterol sulfate inhalation aerosol.
read more
Friday, September 25, 2020
The FDA is alerting health care professionals and patients of a recall of all unexpired albuterol sulfate inhalation aerosol manufactured by Catalent for Perrigo due to possible clogging of the inhaler.
read more
Perrigo is taking actions to drive substantial profit growth in 2016 and beyond. In total, the actions are expected to add incremental benefits of $175 million when the full run rate of the plan is achieved.
read more
Perrigo Company has announced that Mr. Sharon Kochan, Perrigo's Executive Vice President and General Manager, International, will have expanded responsibilities that will now include providing leadership and strategic direction to the Company's ...
read more
Thursday, August 09, 2018
Perrigo has entered into a licensing agreement with a subsidiary of Merck for the exclusive rights in the United States to pursue regulatory approval for an OTC Nasonex Nasal Spray.
read more
Monday, February 27, 2017
Perrigo Company has announced that Ron Winowiecki, Senior Vice President, Business Finance, has been appointed acting Chief Financial Officer, effective immediately, following the resignation of Judy L. Brown, Executive Vice President, Business ...
read more
Monday, November 27, 2017
Perrigo announced the launch of an AB rated generic version of Mycolog II Cream (nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/gram).
read more
Thursday, February 07, 2019
Perrigo has received final approval from the FDA for its AB rated Abbreviated NDA referencing Zovirax Cream, 5% (acyclovir cream, 5%) developed in collaboration with Sol-Gel Technologies.
read more
Quotient Sciences and Permira announced a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient.
read more
Permira, a global private equity firm, has announced that a company backed by the Permira funds has signed a definitive agreement to acquire Lyophilization Services of New England, Inc (“LSNE”), a contract development and manufacturing organization ...
read more
Wednesday, August 07, 2019
Cambrex has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion, including Cambrex’s net debt.
read more